Walid A, Abdulsamad W, Faten M, Thomas L. A chronic myeloid leukemia case with a unique variant Philadelphia translocation: t(9; 22; 21) (q34; q11; p12). Oncol Lett 2012; 3(5): 1027-9.
Boultwood J, Perry J, Zaman R, et al. High-density single nucleotide polymorphism arrayanalysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Leukemia 2010; 24: 1139-45.
Zhang SJ, Shi JY, Li JY. GATA-2L359 V mutation is exclusively associated with CML progression but no other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism. Leuk Res 2009; 33: 1141-3.
Angelini S, Soverini S, Ravegnini G, et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica 2013; 98: 193-200.
Crossman LC, O’Hare T, Lange T, et al. A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib. Leukemia 2005; 19: 1859-62.
Kim DH, Xu W, Ma C, et al. Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia. Blood 2009; 113: 2517-25.
Liu YC, Hsiao HH, Yang WC, et al. MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib. Mol Carcinog 2014; 53: 951-9.
Ma X, Ruan G, Wang Y, et al. Two single-nucleotide polymorphisms with linkage disequilibrium in the human programmed cell death 5 gene 5′ regulatory region affect promoter activity and the susceptibility of chronic myelogenous leukemia in Chinese population. Clin Cancer Res 2005; 11: 8592-9.
Heriberto B, Juan RG, François S, et al. Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia. Oncotarget 2015; 6(34): 36269-77.
Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell 2012; 149: 515-24.
Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-33.
Rukov JL, Shomron N. MicroRNA pharmacogenomics: post-transcriptional regulation of drug response. Trends Mol Med 2011; 17: 412-23.
Sclafani F, Chau I, Cunningham D, et al. Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. Carcinogenesis 2016; 37: 852-7.
Yong M, Chengda Z, Fanyi M, Jiehong K, Weipeng W, Dong H. The SNPs in pre-miRNA are related to the response of capecitabine-based therapy in advanced colon cancer patients. Oncotarget 2018; 9(6): 6793-9.
Sand M, Skrygan M, Sand D, et al. Expression of microRNAs in basal cell carcinoma. Br J Dermatol 2012; 167: 847-55.
Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291(5507): 1304-51.
Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010; 10: 389-402.
Qiaoli Z, Jiang C, Nada H, et al. Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia. J Transl Med 2016; 14: 82.
Kim HK, Prokunina-Olsson L, Chanock SJ. Common genetic variants in miR-1206 (8q24.2) and miR-612 (11q13.3) affect biogenesis of mature miRNA forms. PLoS One 2012; 7: e47454.
Martin-Guerrero I, Gutierrez-Camino A, Lopez-Lopez E, et al. Genetic variants in miRNA processing genes and pre-miRNAs are associated with the risk of chronic lymphocytic leukemia. PLoS One 2015; 10: e0118905.
Huppi K, Volfovsky N, Runfola T, et al. The identification of microRNAs in a genomically unstable region of human chromosome 8q24. Mol Cancer Res 2008; 6: 212-21.
López-López E, Gutiérrez-Camino Á, Piñán MA, et al. Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia. PLoS One 2014; 9: e91261.
Gutierrez-Camino A, Oosterom N, den Hoed MA, et al. The miR-1206 microRNA variant is associated with methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics 2017; 27: 303-6.
Idoia MG, Angela GC, Elixabet LL, et al. Genetic variants in miRNA processing genes and pre-miRNAs are associated with the risk of chronic lymphocytic leukemia. PLoS One 2015; 10(3): e0118905.